-transparent.png){kind=logo}
The effect of riboflavin on six patients with hemolytic anemia due to hereditary pyruvate kinase deficiency was studied. Treatment over a period of four to six months produced no significant hematologic or enzymologic changes in the variants investigated.
Related Publications
K G Blume, and
H Arnold, and
K Hasslinger, and
G W Löhr
May 1975,
Clinica chimica acta; international journal of clinical chemistry,
K G Blume, and
H Arnold, and
K Hasslinger, and
G W Löhr
July 1966,
Archives of internal medicine,
K G Blume, and
H Arnold, and
K Hasslinger, and
G W Löhr
January 1977,
Acta haematologica,
K G Blume, and
H Arnold, and
K Hasslinger, and
G W Löhr
August 1999,
Nihon rinsho. Japanese journal of clinical medicine,
K G Blume, and
H Arnold, and
K Hasslinger, and
G W Löhr
November 1980,
Clinica chimica acta; international journal of clinical chemistry,
K G Blume, and
H Arnold, and
K Hasslinger, and
G W Löhr
December 2010,
Blood cells, molecules & diseases,
K G Blume, and
H Arnold, and
K Hasslinger, and
G W Löhr
June 1977,
The Medical journal of Australia,
K G Blume, and
H Arnold, and
K Hasslinger, and
G W Löhr
January 1990,
Genetic counseling (Geneva, Switzerland),
K G Blume, and
H Arnold, and
K Hasslinger, and
G W Löhr
July 2005,
British journal of haematology,
K G Blume, and
H Arnold, and
K Hasslinger, and
G W Löhr
October 1978,
Haematologica,
